1:11 PM
 | 
Dec 06, 2018
 |  BC Extra  |  Politics & Policy

FDA smoothing the path for class-wide cancer companion diagnostics

FDA Thursday announced the availability of draft guidance that is intended to make it easier for cancer companion diagnostics to be approved for a class of drugs, rather than only for a specific drug.

FDA Commissioner Scott Gottlieb discussed the draft guidance with BioCentury in November, saying it would give physicians...

Read the full 242 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >